- Editas Medicine will lay off 180 employees, or about two-thirds of its workforce, over the next six months as part of a broader pivot to focus its dr-g research on “in vivo” gene editing, the biotechnology company said Thursday.
- In October, Editas revealed plans to change course, announcing that it would seek to license out its lead CRISPR medicine for sickle cell disease. That search did not identify a commercial partner, Editas said, leading to the company’s decision to end development of the therapy.
- Among those departing the company is Baisong Mei, the company’s chief medical officer. Two members of the board of directors will also resign at the end of the year.
https://www.biopharmadive.com/news/editas-layoffs-reni-cel-discontinue-pivot-in-vio/735465/